Cancer is a disease characterized by alterations in both cell structure and DNA organization. Pathologists have long realized that cancer cells have markedly altered nuclear shapes and patterns of chromatin. The causes of these alterations in nuclear and DNA organization have not been well characterized.
The aim of this research effort is to characterize and elucidate the mechanisms involved in determining the three-- dimensional DNA organization within the cancer cell. The long range goal of the sponsor's laboratory program has been to understand how alterations in cell structure within the cancer cell may contribute to alterations of DNA organization . Utilizing prostate cancer as a model, the laboratory has demonstrated that alterations in cancer cell nuclear morphology correlate with changes in the composition of the nuclear matrix. The nuclear matrix is the structural element which determines in part the three-dimensional organization of the nucleus and is involved in DNA organization and function. The applicant will investigate whether alterations in the nuclear matrix contribute to alterations of DNA organization and therefore, alterations of gene expression observed within cancer cells. Transfection of normal cells with specific oncogenes and putative tumor suppressor genes will be used to better understand their respective roles in altering DNA organization and nuclear matrix composition. Specifically, the three-dimensional organization of DNA within normal prostate cells as well as transformed prostate cancer cells will be investigated utilizing in situ hybridization and confocal microscopy. By utilizing cDNA probes for genes that are located on and off the nuclear matrix, alterations in three-dimensional structural DNA organization will be correlated with changes in nuclear matrix-gene interactions. In addition, alterations in nuclear matrix composition will be investigated utilizing high resolution two-dimensional gel electrophoresis. The second objective of this application is to support the training of a physician as a medical scientist. The applicant aspires to take a clinical education from his medical residency at the University of Chicago and fellowship in medical oncology at Johns Hopkins into a career of independent scholarship in oncology investigation. Toward this goal, Dr. Pienta will train in the Laboratory of Cell Structure and Function at the Johns Hopkins Oncology Center under the guidance of Dr. Donald S. Coffey, the award sponsor. In addition to the rigorous laboratory experience in cellular and molecular biology, Phase I of the award will also encompass a didactic program in cellular and molecular biology. A faculty advisory committee will review Dr. Pienta's progress every four months. After successful completion of Phase I, Dr. Pienta will assume a faculty position to further pursue these studies in Phase II.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (K11)
Project #
5K11CA060156-02
Application #
3086004
Study Section
Cancer Institutional Fellowship Review Committee (CT)
Project Start
1992-09-01
Project End
1994-07-31
Budget Start
1993-09-01
Budget End
1994-07-31
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Smith, D C; Redman, B G; Flaherty, L E et al. (1998) A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 52:257-60
Lehr, J E; Pienta, K J (1998) Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 90:118-23
Pilat, M J; Schwab, E D; Yao, K L et al. (1998) Examination of the DNA methylation properties in nontumorigenic and tumorigenic breast epithelial cell lines. Anticancer Res 18:2575-82
Pilat, M J; Lehr, J E; Quigley, M M et al. (1998) The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model. Oncol Rep 5:889-92
Lehr, J E; Pienta, K J; Yamazaki, K et al. (1998) A model to study c-myc and v-H-ras induced prostate cancer progression in the Copenhagen rat. Cell Mol Biol (Noisy-le-grand) 44:949-59
Smith, D C; Dunn, R L; Strawderman, M S et al. (1998) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16:1835-43
Pienta, K J; Redman, B G; Bandekar, R et al. (1997) A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50:401-6; discussion 406-7
Replogle-Schwab, T S; Schwab, E D; Pienta, K J (1997) Development of doxorubicin resistant rat prostate cancer cell lines. Anticancer Res 17:4535-8
Yee, C S; Schwab, E D; Lehr, J E et al. (1997) The effect of castanospermine on the metastatic properties of prostate cancer cells. Anticancer Res 17:3659-63
Smith, D C; Pienta, K J (1997) The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer. Urol Clin North Am 24:433-7

Showing the most recent 10 out of 35 publications